NEW
YORK, July 25, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Marinus
Pharmaceuticals, Inc. (NASDAQ: MRNS).
Shareholders who purchased shares of MRNS during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/?id=91974&from=4
CLASS PERIOD: March 17,
2021 to May 7, 2024
ALLEGATIONS: The complaint alleges that during the
class period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) defendants
understated the risk of failure to meet the early-stopping criteria
in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2)
defendants did not disclose that a possible consequence of failing
to meet the early stopping criteria in the RAISE trial would be
that Marinus would stop the separate Phase 3 RAISE II trial; and
(3) as a result, defendants' statements about its business,
operations, and prospects, were materially false and misleading
and/or lacked a reasonable basis at all times.
DEADLINE: August 5, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/?id=91974&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of MRNS during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is August 5, 2024. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross
Law Firm is committed to ensuring that companies adhere to
responsible business practices and engage in good corporate
citizenship. The firm seeks recovery on behalf of investors who
incurred losses when false and/or misleading statements or the
omission of material information by a company lead to artificial
inflation of the company's stock. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-notifies-marinus-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline--mrns-302205952.html
SOURCE The Gross Law Firm